EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

Adrián Martín-Gutiérrez, Javier Loricera, Javier Narváez, Vicente Aldasoro, Olga Maiz, Paloma Vela, Susana Romero-Yuste, Eugenio de Miguel, Eva Galíndez-Agirregoikoa, Jesús C Fernández-López, Iván Ferraz-Amaro, Julio Sánchez-Martín und 6 weitere

European Journal of Internal Medicine · 2024

DOI: 10.1016/j.ejim.2024.06.013 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Adrián Martín-Gutiérrez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aortitis, Giant Cell Arteritis, Heart Aneurysm. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Aortitis in Giant Cell Arteritis (GCA-aortitis) is a frequent complication that may lead to aneurysms. Tocilizumab (TCZ) was approved in GCA, but the efficacy in GCA-aortitis and aneurysms has not been analyzed to date. Our aim was to assess the effectiveness and safety of TCZ in a wide series of GCA-aortitis and aneurysms. METHODS: Multicentre observational study with GCA-aortitis treated with TCZ. GCA was diagnosed by: a) ACR criteria, b) temporal artery biopsy, and/or c) imaging techniques. Aortitis was diagnosed mainly by PET/CT. Main outcomes were EULAR and imaging remission. Others were clinical remission, analytical normalization, corticosteroid-sparing effect, and the prevention and improvement of aneurysms. RESULTS: 196 patients with GCA-aortitis treated with TCZ. After 6 months, 72.2% reached EULAR remission but only 12% an imaging remission; increasing up-to 81.4% and 31.8%, respectively, at 24 months. A rapid clinical remission, ESR and CRP normalization was observed in 47.4%, 84.3% and 55.6%, at 1 month, increasing to 89.6%, 85.3% and 80.3% at 24 months, respectively. Aneurysms were present in 10 (5%) patients. Five of them required early surgery, while 3 others enlarged. No patient on TCZ therapy developed aneurysms during follow-up. CONCLUSION: In patients with GCA-aortitis treated with TCZ, a rapid and maintained clinical and analytical improvement was observed. However, there was an uncoupling between clinical and EULAR remission with imaging remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAortitisGiant Cell ArteritisHeart AneurysmAgedAged, 80 and overFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRemission InductionTreatment Outcome

Stichwörter der Autor:innen

Analytical remissionAortitisClinical remissionComplete remissionEULAR remissionPET/ CT-remissionTocilizumab

Substanzen

Antibodies, Monoclonal, Humanizedtocilizumab

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
  • Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain.
  • Department of Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Department of Rheumatology, Hospital Universitario de Donosti, San Sebastián, Spain.
  • Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain.
  • Department of Rheumatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.

Zitieren

APA

Martín-Gutiérrez, A., Loricera, J., Narváez, J., Aldasoro, V., Maiz, O., Vela, P., Romero-Yuste, S., de Miguel, E., Galíndez-Agirregoikoa, E., Fernández-López, J. C., Ferraz-Amaro, I., Sánchez-Martín, J., Moya, P., Campos, C., López-Gutiérrez, F., Castañeda, S., Blanco, R., & Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group (2024). Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.06.013

Vancouver

Martín-Gutiérrez A, Loricera J, Narváez J, Aldasoro V, Maiz O, Vela P, et al. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.06.013

BibTeX
@article{MartnGutirrez2024,
  author = {Martín-Gutiérrez, Adrián and Loricera, Javier and Narváez, Javier and Aldasoro, Vicente and Maiz, Olga and Vela, Paloma and Romero-Yuste, Susana and de Miguel, Eugenio and Galíndez-Agirregoikoa, Eva and Fernández-López, Jesús C and Ferraz-Amaro, Iván and Sánchez-Martín, Julio and Moya, Patricia and Campos, Cristina and López-Gutiérrez, Fernando and Castañeda, Santos and Blanco, Ricardo and Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group},
  title = {Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  doi = {10.1016/j.ejim.2024.06.013}
}
Kostenlos starten →